Nicolas Tricaud PhD, a world-renown scientist in the field of the myelin and peripheral nerves, announces
the creation of Nervosave Therapeutics S.A.S. in Montpellier.
The startup is a spin-off from Inserm, with support by SATT AxLR, Occitanie Region, and Montpellier BIC. They develop innovative therapeutic products to treat demyelinating diseases in the peripheral nervous system.
The company’s first product is a gene therapy to treat patients suffering from Charcot-Marie-Tooth disease type 1A (CMT1A)*. In addition, Nervosave Therapeutics is developing a platform to treat demyelinating CMT diseases and other acquired demyelinating peripheral neuropathic diseases, such as diabetic peripheral neuropathy and Guillain-Barré syndrome.
This is the first biotech that is totally dedicated to treating peripheral nerve diseases. Our goal is to benefit from the extraordinary potential of gene therapy and other innovative therapies to make Nervosave Therapeutics the world leader in the field of peripheral nervous system disorders within the next five years. The many patients suffering from these terrible disorders – most of which remain untreated – deserve our utmost attention,” highlights Nicolas Tricaud, the company’s CEO and Scientific Director.
Nervosave Therapeutics, another bright star for
Med Vallée.
* Charcot-Marie-Tooth diseases are serious, debilitating, chronic neuromuscular disorders that mainly affect peripheral nerves. These disorders, for which there is currently no treatment, and which are mostly triggered by genetic factors, impact about 3 million people around the world (source: Orhpanet). 
